Targeting sphingosine-1-phosphate in hematologic malignancies

Anti-Cancer Agents in Medicinal Chemistry

Volumn 11, Issue 9, 2011, Pages 794-798

  Stevenson, Christina E ^a   Takabe, Kazuaki ^a   Nagahashi, Masayuki ^a   Milstien, Sheldon ^a   Spiegel, Sarah ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hematologic malignancies; Leukemia; Lymphoma; Sphingosine kinase; Sphingosine 1 phosphate; Sphingosine 1 phosphate receptors

Indexed keywords

2 (4 HYDROXYANILINO) 4 (4 CHLOROPHENYL)THIAZOLE; 4 [[4 (4 CHLOROPHENYL) 2 THIAZOYL]AMINO]PHENOL; ANTINEOPLASTIC AGENT; CELL SURFACE RECEPTOR; DASATINIB; DAUNORUBICIN; F 12509A; FINGOLIMOD; G PROTEIN COUPLED RECEPTOR; IMATINIB; N METHYL 5 (4' PENTYLPHENYL) 2 AMINOPENT 4 ENE 1,3 DIOL; N,N DIMETHYLSPHINGOSINE; NILOTINIB; SPHINGOSINE 1 PHOSPHATE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; SPHINGOSINE KINASE 1; SPHINGOSINE KINASE 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; AUTOCRINE EFFECT; B CELL LEUKEMIA; B CELL LYMPHOMA; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CHRONIC MYELOID LEUKEMIA; DRUG TARGETING; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHATIC LEUKEMIA; LYMPHOBLASTOMA; NONHUMAN; PARACRINE SIGNALING; RECEPTOR UPREGULATION; REVIEW; SIGNAL TRANSDUCTION;

EID: 80054060839     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152011797655122     Document Type: Review

References (45)

1. Milstien, S.; Spiegel, S. Targeting sphingosine-1-phosphate: A novel avenue for cancer therapeutics. Cancer Cell, 2006, 9 (3), 148-150.
2. Pyne, N. J.; Pyne, S. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer, 2010, 10 (7), 489-503.
3. Cuvillier, O.; Pirianov, G.; Kleuser, B.; Vanek, P. G.; Coso, O. A.; Gutkind, S.; Spiegel, S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature, 1996, 381 (6585), 800-803.
4. Takabe, K.; Kim, R. H.; Allegood, J. C.; Mitra, P.; Ramachandran, S.; Nagahashi, M.; Harikumar, K. B.; Hait, N. C.; Milstien, S.; Spiegel, S. Estradiol induces export of sphingosine 1-phosphate from breast cancer cells via ABCC1 and ABCG2. J. Biol. Chem., 2010, 285 (14), 10477-10486.
5. Lee, H.; Deng, J.; Kujawski, M.; Yang, C.; Liu, Y.; Herrmann, A.; Kortylewski, M.; Horne, D.; Somlo, G.; Forman, S.; Jove, R.; Yu, H. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat. Med., 2010, 6(12), 1421-1428.
6. Alvarez, S. E.; Harikumar, K. B.; Hait, N. C.; Allegood, J.; Strub, G. M.; Kim, E. Y.; Maceyka, M.; Jiang, H.; Luo, C.; Kordula, T.; Milstien, S.; Spiegel, S. Sphingosine-1-phosphate is a missing cofactor for the E3 ubiquitin ligase TRAF2. Nature, 2010, 465 (7301), 1084-1088.
7. Sobue, S.; Nemoto, S.; Murakami, M.; Ito, H.; Kimura, A.; Gao, S.; Furuhata, A.; Takagi, A.; Kojima, T.; Nakamura, M.; Ito, Y.; Suzuki, M.; Banno, Y.; Nozawa, Y.; Murate, T. Implications of sphingosine kinase 1 expression level for the cellular sphingolipid rheostat: relevance as a marker for daunorubicin sensitivity of leukemia cells. Int. J. Hematol., 2008, 87 (3), 266-275.
8. Sobue, S.; Iwasaki, T.; Sugisaki, C.; Nagata, K.; Kikuchi, R.; Murakami, M.; Takagi, A.; Kojima, T.; Banno, Y.; Akao, Y.; Nozawa, Y.; Kannagi, R.; Suzuki, M.; Abe, A.; Naoe, T.; Murate, T. Quantitative RT-PCR analysis of sphingolipid metabolic enzymes in acute leukemia and myelodysplastic syndromes. Leukemia, 2006, 20 (11), 2042-2046.
9. Le Scolan, E.; Pchejetski, D.; Banno, Y.; Denis, N.; Mayeux, P.; Vainchenker, W.; Levade, T.; Moreau-Gachelin, F. Overexpression of sphingosine kinase 1 is an oncogenic event in erythroleukemic progression. Blood, 2005, 106 (5), 1808-1816.
10. Igarashi, N.; Okada, T.; Hayashi, S.; Fujita, T.; Jahangeer, S.; Nakamura, S. I. Sphingosine kinase 2 is a nuclear protein and inhibits DNA synthesis. J. Biol. Chem., 2003, 278 (47), 46832-46839.
11. Maceyka, M.; Sankala, H.; Hait, N. C.; Le Stunff, H.; Liu, H.; Toman, R.; Collier, C.; Zhang, M.; Satin, L.; Merrill, A. H., Jr.; Milstien, S.; Spiegel, S. Sphk1 and Sphk2: Sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J. Biol. Chem., 2005, 280 (44), 37118-37129.
12. Hait, N. C.; Allegood, J.; Maceyka, M.; Strub, G. M.; Harikumar, K. B.; Singh, S. K.; Luo, C.; Marmorstein, R.; Kordula, T.; Milstien, S.; Spiegel, S. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science, 2009, 325 (5945), 1254-1257.
13. Lane, A. A.; Chabner, B. A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol., 2009, 27 (32), 5459-5468.
14. Shatrov, V. A.; Lehmann, V.; Chouaib, S. Sphingosine-1- phosphate mobilizes intracellular calcium and activates transcription factor NF-kB in U937 cells. Biochem. Biophys. Res. Commun., 1997, 234 (1), 121-124.
15. Cuvillier, O.; Levade, T. Sphingosine 1-phosphate antagonizes apoptosis of human leukemia cells by inhibiting release of cytochrome c and Smac/DIABLO from mitochondria. Blood, 2001, 98 (9), 2828-2836.
16. Bonhoure, E.; Pchejetski, D.; Aouali, N.; Morjani, H.; Levade, T.; Kohama, T.; Cuvillier, O. Overcoming MDR-associated chemoresistance in HL-60 acute myeloid leukemia cells by targeting sphingosine kinase-1. Leukemia, 2006, 20 (1), 95-102.
17. Zhang, R.; Shah, M. V.; Yang, J.; Nyland, S. B.; Liu, X.; Yun, J. K.; Albert, R.; Loughran, T. P., Jr. Network model of survival signaling in large granular lymphocyte leukemia. Proc. Natl. Acad. Sci. U.S.A., 2008, 105 (42), 16308-16313.
18. Kilbey, A.; Terry, A.; Jenkins, A.; Borland, G.; Zhang, Q.; Wakelam, M. J.; Cameron, E. R.; Neil, J. C. Runx regulation of sphingolipid metabolism and survival signaling. Cancer Res., 2010, 70 (14), 5860-5869.
19. Li, Q. F.; Wu, C. T.; Duan, H. F.; Sun, H. Y.; Wang, H.; Lu, Z. Z.; Zhang, Q. W.; Liu, H. J.; Wang, L. S. Activation of sphingosine kinase mediates suppressive effect of interleukin-6 on human multiple myeloma cell apoptosis. Br. J. Haematol., 2007, 138 (5), 632-639.
20. Baran, Y.; Salas, A.; Senkal, C. E.; Gunduz, U.; Bielawski, J.; Obeid, L. M.; Ogretmen, B. Alterations of ceramide/sphingosine 1- phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J. Biol. Chem., 2007, 282 (15), 10922-10934.
21. Li, Q. F.; Huang, W. R.; Duan, H. F.; Wang, H.; Wu, C. T.; Wang, L. S. Sphingosine kinase-1 mediates BCR/ABL-induced upregulation of Mcl-1 in chronic myeloid leukemia cells. Oncogene, 2007, 26 (57), 7904-7908.
22. Bonhoure, E.; Lauret, A.; Barnes, D. J.; Martin, C.; Malavaud, B.; Kohama, T.; Melo, J. V.; Cuvillier, O. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia, 2008, 22 (5), 971-979.
23. Stam, J. C.; Michiels, F.; Kammen, R. A.; Moolenaar, W. H.; Collard, J. G. Invasion of T-lymphoma cells: cooperation between Rho family GTPases and lysophospholipid receptor signaling. EMBO J., 1998, 17 (14), 4066-4074.
24. Li, Q. F.; Wu, C. T.; Guo, Q.; Wang, H.; Wang, L. S. Sphingosine 1-phosphate induces Mcl-1 upregulation and protects multiple myeloma cells against apoptosis. Biochem. Biophys. Res. Commun., 2008, 371 (1), 159-162.
25. Kothapalli, R.; Kusmartseva, I.; Loughran, T. P. Characterization of a human sphingosine-1-phosphate receptor gene (S1P5) and its differential expression in LGL leukemia. Biochim. Biophys. Acta, 2002, 1579 (2-3), 117-123.
26. Nishimura, H.; Akiyama, T.; Monobe, Y.; Matsubara, K.; Igarashi, Y.; Abe, M.; Sugihara, T.; Sadahira, Y. Expression of sphingosine- 1-phosphate receptor 1 in mantle cell lymphoma. Mod. Pathol., 2010, 23 (3), 439-449.
27. Feng, H.; Stachura, D. L.; White, R. M.; Gutierrez, A.; Zhang, L.; Sanda, T.; Jette, C. A.; Testa, J. R.; Neuberg, D. S.; Langenau, D. M.; Kutok, J. L.; Zon, L. I.; Traver, D.; Fleming, M. D.; Kanki, J. P.; Look, A. T. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. Cancer Cell, 2010, 18 (4), 353-366.
28. Cattoretti, G.; Mandelbaum, J.; Lee, N.; Chaves, A. H.; Mahler, A. M.; Chadburn, A.; Dalla-Favera, R.; Pasqualucci, L.; MacLennan, A. J. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. Cancer Res., 2009, 69 (22), 8686-8692.
29. Edsall, L. C.; Van Brocklyn, J. R.; Cuvillier, O.; Kleuser, B.; Spiegel, S. N,N-Dimethylsphingosine is a potent competitive inhibitor of sphingosine kinase but not of protein kinase C: modulation of cellular levels of sphingosine 1-phosphate and ceramide. Biochemistry, 1998, 37 (37), 12892-12898.
30. Kim, B. M.; Choi, Y. J.; Han, Y.; Yun, Y. S.; Hong, S. H. N,N-dimethyl phytosphingosine induces caspase-8-dependent cytochrome c release and apoptosis through ROS generation in human leukemia cells. Toxicol. Appl. Pharmacol., 2009, 239 (1), 87-97.
31. Kono, K.; Sugiura, M.; Kohama, T. Inhibition of recombinant sphingosine kinases by novel inhibitors of microbial origin, F- 12509A and B-5354c. J. Antibiot. (Tokyo), 2002, 55 (1), 99-103.
32. French, K. J.; Zhuang, Y.; Maines, L. W.; Gao, P.; Wang, W.; Beljanski, V.; Upson, J. J.; Green, C. L.; Keller, S. N.; Smith, C. D. Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J. Pharmacol. Exp. Ther., 2010, 333 (1), 129-139.
33. Beljanski, V.; Lewis, C. S.; Smith, C. D. Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol. Ther., 2011, 11 (5), 524-534.
34. Antoon, J. W.; White, M. D.; Slaughter, E. M.; Driver, J. L.; Khalili, H. S.; Elliott, S.; Smith, C. D.; Burow, M. E.; Beckman, B. S. Targeting NFkB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol. Ther., 2011, 11 (7), 678-689.
35. Paugh, S. W.; Paugh, B. S.; Rahmani, M.; Kapitonov, D.; Almenara, J. A.; Kordula, T.; Milstien, S.; Adams, J. K.; Zipkin, R. E.; Grant, S.; Spiegel, S. A selective sphingosine kinase 1 inhibitor integrates multiple molecular therapeutic targets in human leukemia. Blood, 2008, 112 (4), 1382-1391.
36. Brinkmann, V.; Billich, A.; Baumruker, T.; Heining, P.; Schmouder, R.; Francis, G.; Aradhye, S.; Burtin, P. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat. Rev. Drug Discov., 2010, 9 (11), 883-897.
37. Mandala, S.; Hajdu, R.; Bergstrom, J.; Quackenbush, E.; Xie, J.; Milligan, J.; Thornton, R.; Shei, G. J.; Card, D.; Keohane, C.; Rosenbach, M.; Hale, J.; Lynch, C. L.; Rupprecht, K.; Parsons, W.; Rosen, H. Alteration of lymphocyte trafficking by sphingosine-1- phosphate receptor agonists. Science, 2002, 296 (5566), 346-349.
38. Li, D.; Zhang, Y.; Hu, X.; Cao, W.; Huang, W. Role of extracelluar regulated protein kinases in FTY720-induced apoptosis of leukemia cell lines HL-60 and U937. J. Huazhong Univ. Sci. Technolog. Med. Sci., 2004, 24 (1), 45-47.
39. Shah, M. V.; Zhang, R.; Irby, R.; Kothapalli, R.; Liu, X.; Arrington, T.; Frank, B.; Lee, N. H.; Loughran, T. P., Jr. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood, 2008, 112 (3), 770-781.
40. Liu, Q.; Zhao, X.; Frissora, F.; Ma, Y.; Santhanam, R.; Jarjoura, D.; Lehman, A.; Perrotti, D.; Chen, C. S.; Dalton, J. T.; Muthusamy, N.; Byrd, J. C. FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood, 2008, 111 (1), 275-284.
41. Matsuoka, Y.; Nagahara, Y.; Ikekita, M.; Shinomiya, T. A novel immunosuppressive agent FTY720 induced Akt dephosphorylation in leukemia cells. Br. J. Pharmacol., 2003, 138 (7), 1303-1312.
42. Don, A. S.; Martinez-Lamenca, C.; Webb, W. R.; Proia, R. L.; Roberts, E.; Rosen, H. Essential requirement for sphingosine kinase 2 in a sphingolipid apoptosis pathway activated by FTY720 analogs. J. Biol. Chem., 2007, 282 15833-15842.
43. Payne, S. G.; Oskeritzian, C. A.; Griffiths, R.; Subramanian, P.; Barbour, S. E.; Chalfant, C. E.; Milstien, S.; Spiegel, S. The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood, 2007, 109 1077-1085.
44. Neviani, P.; Santhanam, R.; Oaks, J. J.; Eiring, A. M.; Notari, M.; Blaser, B. W.; Liu, S.; Trotta, R.; Muthusamy, N.; Gambacorti- Passerini, C.; Druker, B. J.; Cortes, J.; Marcucci, G.; Chen, C. S.; Verrills, N. M.; Roy, D. C.; Caligiuri, M. A.; Bloomfield, C. D.; Byrd, J. C.; Perrotti, D. FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia. J. Clin. Invest., 2007, 117 (9), 2408-2421.
45. Roberts, K. G.; Smith, A. M.; McDougall, F.; Carpenter, H.; Horan, M.; Neviani, P.; Powell, J. A.; Thomas, D.; Guthridge, M. A.; Perrotti, D.; Sim, A. T.; Ashman, L. K.; Verrills, N. M. Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c- KIT+ cancers. Cancer Res., 2010, 70 (13), 5438-5447.